BofA analyst Tazeen Ahmad upgraded Kymera Therapeutics (KYMR) to Buy from Neutral with a price target of $51, up from $44.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
- Kymera Therapeutics Discusses Phase 1 Study Results
- Kymera Therapeutics Announces Positive Phase 1 Study Results
- Kymera Therapeutics announces first-in-human results for Phase 1 trial of KT-621
- Cautious Hold Rating for Kymera Therapeutics Amid Anticipation of STAT6 Degrader Data